Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 5.19
CBRX's Cash to Debt is ranked higher than
72% of the 750 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. CBRX: 5.19 )
CBRX' s 10-Year Cash to Debt Range
Min: 0.03   Max: No Debt
Current: 5.19

Equity to Asset 0.78
CBRX's Equity to Asset is ranked higher than
82% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.60 vs. CBRX: 0.78 )
CBRX' s 10-Year Equity to Asset Range
Min: -1.03   Max: 0.85
Current: 0.78

-1.03
0.85
F-Score: 5
Z-Score: -0.59
M-Score: 91.61
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) 20.10
CBRX's Operating margin (%) is ranked higher than
90% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.34 vs. CBRX: 20.10 )
CBRX' s 10-Year Operating margin (%) Range
Min: -717.08   Max: 53.25
Current: 20.1

-717.08
53.25
Net-margin (%) 22.94
CBRX's Net-margin (%) is ranked higher than
94% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. CBRX: 22.94 )
CBRX' s 10-Year Net-margin (%) Range
Min: -735.65   Max: 47.67
Current: 22.94

-735.65
47.67
ROE (%) 14.30
CBRX's ROE (%) is ranked higher than
90% of the 716 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. CBRX: 14.30 )
CBRX' s 10-Year ROE (%) Range
Min: -709.28   Max: 99.5
Current: 14.3

-709.28
99.5
ROA (%) 11.16
CBRX's ROA (%) is ranked higher than
94% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.95 vs. CBRX: 11.16 )
CBRX' s 10-Year ROA (%) Range
Min: -185.12   Max: 56.89
Current: 11.16

-185.12
56.89
ROC (Joel Greenblatt) (%) 31.43
CBRX's ROC (Joel Greenblatt) (%) is ranked higher than
88% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.63 vs. CBRX: 31.43 )
CBRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1904.92   Max: 596.64
Current: 31.43

-1904.92
596.64
Revenue Growth (%) -19.50
CBRX's Revenue Growth (%) is ranked lower than
54% of the 549 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. CBRX: -19.50 )
CBRX' s 10-Year Revenue Growth (%) Range
Min: -41.8   Max: 85.1
Current: -19.5

-41.8
85.1
» CBRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

CBRX Guru Trades in Q1 2013

Jim Simons 207,249 sh (New)
» More
Q2 2013

CBRX Guru Trades in Q2 2013

Jim Simons 121,701 sh (-41.28%)
» More
Q3 2013

CBRX Guru Trades in Q3 2013

Jim Simons 184,950 sh (+1115.74%)
» More
Q4 2013

CBRX Guru Trades in Q4 2013

Jim Simons 164,250 sh (-11.19%)
» More
» Details

Insider Trades

Latest Guru Trades with CBRX

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2011-12-31 Sold Out 0.0036%$15.28 - $21.6 $ 6.55-65%0
Joel Greenblatt 2011-09-30 New Buy$15.68 - $27.12 $ 6.55-68%11210
Richard Perry 2011-06-30 Sold Out 0.21%$23.92 - $32.24 $ 6.55-76%0
Richard Perry 2011-03-31 New Buy0.21%$17.2 - $31.92 $ 6.55-73%1682243
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 12.70
CBRX's P/E(ttm) is ranked higher than
91% of the 527 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.60 vs. CBRX: 12.70 )
CBRX' s 10-Year P/E(ttm) Range
Min: 4.79   Max: 296.3
Current: 12.7

4.79
296.3
P/B 1.70
CBRX's P/B is ranked higher than
79% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.84 vs. CBRX: 1.70 )
CBRX' s 10-Year P/B Range
Min: 1.51   Max: 63.23
Current: 1.7

1.51
63.23
P/S 2.53
CBRX's P/S is ranked higher than
62% of the 717 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.95 vs. CBRX: 2.53 )
CBRX' s 10-Year P/S Range
Min: 1.45   Max: 33.33
Current: 2.53

1.45
33.33
PFCF 11.40
CBRX's PFCF is ranked higher than
92% of the 328 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.79 vs. CBRX: 11.40 )
CBRX' s 10-Year PFCF Range
Min: 3.7   Max: 95.11
Current: 11.4

3.7
95.11
EV-to-EBIT 11.10
CBRX's EV-to-EBIT is ranked higher than
83% of the 593 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.45 vs. CBRX: 11.10 )
CBRX' s 10-Year EV-to-EBIT Range
Min: 1.8   Max: 202.5
Current: 11.1

1.8
202.5

Valuation & Return

vs
industry
vs
history
Price/Net Cash 10.60
CBRX's Price/Net Cash is ranked higher than
55% of the 219 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.70 vs. CBRX: 10.60 )
CBRX' s 10-Year Price/Net Cash Range
Min: 2.41   Max: 22.47
Current: 10.6

2.41
22.47
Price/Net Current Asset Value 5.40
CBRX's Price/Net Current Asset Value is ranked higher than
69% of the 317 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.80 vs. CBRX: 5.40 )
CBRX' s 10-Year Price/Net Current Asset Value Range
Min: 2.07   Max: 274.51
Current: 5.4

2.07
274.51
Price/Tangible Book 2.40
CBRX's Price/Tangible Book is ranked higher than
70% of the 639 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.10 vs. CBRX: 2.40 )
CBRX' s 10-Year Price/Tangible Book Range
Min: 1.77   Max: 118.37
Current: 2.4

1.77
118.37
Price/DCF (Projected) 7.60
CBRX's Price/DCF (Projected) is ranked lower than
70% of the 349 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. CBRX: 7.60 )
CBRX' s 10-Year Price/DCF (Projected) Range
Min: 2.08   Max: 7.69
Current: 7.6

2.08
7.69
Price/Median PS Value 0.60
CBRX's Price/Median PS Value is ranked higher than
93% of the 675 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.10 vs. CBRX: 0.60 )
CBRX' s 10-Year Price/Median PS Value Range
Min: 0.44   Max: 17.11
Current: 0.6

0.44
17.11
Price/Graham Number 1.10
CBRX's Price/Graham Number is ranked higher than
83% of the 470 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.20 vs. CBRX: 1.10 )
CBRX' s 10-Year Price/Graham Number Range
Min: 0.66   Max: 44.59
Current: 1.1

0.66
44.59
Earnings Yield (Greenblatt) 9.00
CBRX's Earnings Yield (Greenblatt) is ranked higher than
86% of the 595 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. CBRX: 9.00 )
CBRX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.5   Max: 54.1
Current: 9

0.5
54.1
Forward Rate of Return (Yacktman) -7.58
CBRX's Forward Rate of Return (Yacktman) is ranked higher than
57% of the 531 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.45 vs. CBRX: -7.58 )
CBRX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -27.8   Max: 4.2
Current: -7.58

-27.8
4.2

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:CLB.Germany
Columbia Laboratories, Inc., is in the business of developing, manufacturing and selling pharmaceutical products that utilize its proprietary bioadhesive drug delivery technologies to treat various medical conditions. It is focused in developing drugs that improve treatment options for women's health, an area where it have a rich heritage and proven capabilities. It has developed and brought to market five bioadhesive vaginal gel products that provide patient-friendly solutions for infertility, pregnancy support, amenorrhea, and other gynecologic conditions. The Company's Progesterone Products include Crinone and Prochieve. Crinone is a sustained release gel that delivers natural progesterone vaginally. Crinone utilizes the company's patented BDS, which enables the progesterone to achieve a preferential uptake of drug from the vagina to the uterus, or a "First Uterine Pass Effect." The product is available in both 4% and 8% concentrations, and in the U.S. is also known under the trade name Prochieve. Women's Health Market include STRIANT which utilizes the BDS to achieve controlled and sustained delivery of testosterone via the buccal cavity - the small depression in the mouth where the gum meets the upper lip above the incisor teeth. STRIANT is absorbed into the bloodstream and delivers testosterone directly into the superior vena cava (major blood vessel), bypassing the gastrointestinal system and liver. All of the products it has developed utilize its Bioadhesive Delivery System ("BDS"), which consists mainly of a polymer (polycarbophil) and an active ingredient. The BDS is based upon the principle of bioadhesion, a process by which the polymer adheres to epithelial surfaces or mucosa. Its vaginal products adhere to the vaginal epithelium; the buccal products adhere to the mucosal membrane of the gum and cheek. The polymer remains attached to epithelial surfaces or mucosa and is discharged upon normal cell turnover, a physiological process that, depending upon the area of the body, occurs every 12 to 72 hours, or longer. Both vaginal and buccal BDS products provide sustained and controlled delivery of active drug ingredients. Its extended period of attachment permits use of BDS in products when extended duration of effectiveness is desirable or required. It is substantially dependent on three third-party manufacturers for the products that it sells to marketing partners in the U.S. and around the world. It's Crinone and Prochieve vaginal gel products are manufactured in bulk by Fleet Laboratories Limited, Watford, Herts, United Kingdom ("Fleet") and filled into overwrapped single-use disposable applicators by Maropack AG, Zell, Switzerland ("Maropack"). Its customers include trade customers, such as drug wholesalers, specialty pharmacies, and chain drug stores, and its marketing partners. The Company and its marketing partners compete against established pharmaceutical and consumer product companies which market products addre

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide